Lisa Holper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lisa Holper has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
- Felix Scholkmann
Department of Neonatology, University Hospital Zurich, University of Zurich, Frauenklinikstrasse 10, 8001 Zurich, Switzerland
16 shared publications - Kynan Eng
Institute of Neuroinformatics, University of Zürich and ETH Zürich, Zürich, Switzerland
14 shared publications Martin Wolf
12 shared publicationsDaniel Kiper
8 shared publications- Martin Wolf
University Hospital Zurich, University of Zurich, Biomedical Optics Research Laboratory, Department of Neonatology, Zurich, Switzerland
7 shared publications - Andreas Mokros
Fakultät für Psychologie, FernUniversität in Hagen, Hagen, Deutschland
5 shared publications
Latest Publications
- 1 October 2026
- Published by American Psychological Association (APA) in Psychological Assessment
- Vol. 38 (10) , 683-703
Risk assessment instruments for predicting the risk of sexual recidivism: A meta-analytic comparison of 10 instruments.
Risk assessment instruments are commonly used to predict the probability of recidivism among individuals with criminal histories. This meta-analysis synthesizes evidence on the predictive validity of ten instruments for assessing sexual recidivism risk: MnSOST-R, RM2000/S, RRASOR, SORAG, Static-2002, Static-2002 R, Static-99, Static-99 R, SVR-20, and VRS-SO. It includes 162 studies involving 155,442 individuals, published from 1997 to 2024. Results suggested moderate to high predictive validity for most instruments in predicting sexual recidivism and other outcomes, such as violent, sexual-violent, general, and any recidivism. The VRS-SO showed the highest predictive value for sexual recidivism but did not differ from other tools significantly. The SORAG had the highest predictive value for sexual-violent, general, and any recidivism, significantly outperforming the Static-99. The RRASOR had a moderate predictive value for sexual recidivism, but the lowest effect size for all other outcomes. A moderator analysis revealed that mean interrater reliability and mean offender age significantly affected the instruments' predictive validity. This work represents the largest synthesis of risk assessment instruments for sexual recidivism risk to date. The findings support the viability of all instruments examined in forensic practice. Their predictive validity did, however, overlap considerably, except for the more substantial effects of the VRS-SO and the SORAG, and the weaker effect of the RRASOR. Given the overall moderate predictive validity, the instruments should be used in conjunction with other information to guide decision making within the criminal justice system. (PsycInfo Database Record (c) 2026 APA, all rights reserved).
- 1 October 2026
- Published by American Psychological Association (APA) in Psychological Assessment
- Vol. 38 (10) , 683-703
Risk assessment instruments for predicting the risk of sexual recidivism: A meta-analytic comparison of 10 instruments.
Risk assessment instruments are commonly used to predict the probability of recidivism among individuals with criminal histories. This meta-analysis synthesizes evidence on the predictive validity of ten instruments for assessing sexual recidivism risk: MnSOST-R, RM2000/S, RRASOR, SORAG, Static-2002, Static-2002 R, Static-99, Static-99 R, SVR-20, and VRS-SO. It includes 162 studies involving 155,442 individuals, published from 1997 to 2024. Results suggested moderate to high predictive validity for most instruments in predicting sexual recidivism and other outcomes, such as violent, sexual-violent, general, and any recidivism. The VRS-SO showed the highest predictive value for sexual recidivism but did not differ from other tools significantly. The SORAG had the highest predictive value for sexual-violent, general, and any recidivism, significantly outperforming the Static-99. The RRASOR had a moderate predictive value for sexual recidivism, but the lowest effect size for all other outcomes. A moderator analysis revealed that mean interrater reliability and mean offender age significantly affected the instruments' predictive validity. This work represents the largest synthesis of risk assessment instruments for sexual recidivism risk to date. The findings support the viability of all instruments examined in forensic practice. Their predictive validity did, however, overlap considerably, except for the more substantial effects of the VRS-SO and the SORAG, and the weaker effect of the RRASOR. Given the overall moderate predictive validity, the instruments should be used in conjunction with other information to guide decision making within the criminal justice system. (PsycInfo Database Record (c) 2026 APA, all rights reserved).
- Open Access
- 4 March 2025
- Published by Taylor & Francis in Journal of Personality Assessment
- Vol. 107 (5) , 547-562
Criterion Validity of the Psychopathy Checklist in Legal Contexts: An Updated Meta-Analysis
The Psychopathy Checklist (PCL) scales are the most widely used instruments in the assessment of psychopathic personality traits. This updated meta-analysis represents the most extensive synthesis of the PCL scales' criterion validity regarding recidivism and institutional outcomes in legal contexts. According to the results, the PCL total score and Factor 2 criterion validity were moderate and significantly higher for Factor 2 than the total score. The criterion validity of Factor 1 was small and significantly lower than Factor 2 and the total score. The criterion validity of the PCL total score varied considerably between outcomes, with moderate effect sizes for general and violent recidivism, institutional misconduct and violence, and small effect sizes for sexual and intimate partner violence recidivism. A moderator analysis indicated country and sex as the only significant predictors moderating the PCL scales' criterion validity. The total score and Factor 2 were less predictive in the United States than in Canada and Europe for institutional violence. Factor 1 was more predictive in females than males for general and violent recidivism. The present findings may support decision-makers in interpreting the prognostic value and limitations of the PCL scales in the criminal justice system. .
- 4 March 2025
- Published by Taylor & Francis in Journal of Personality Assessment
- Vol. 107 (5) , 547-562
Open AccessCriterion Validity of the Psychopathy Checklist in Legal Contexts: An Updated Meta-Analysis
The Psychopathy Checklist (PCL) scales are the most widely used instruments in the assessment of psychopathic personality traits. This updated meta-analysis represents the most extensive synthesis of the PCL scales' criterion validity regarding recidivism and institutional outcomes in legal contexts. According to the results, the PCL total score and Factor 2 criterion validity were moderate and significantly higher for Factor 2 than the total score. The criterion validity of Factor 1 was small and significantly lower than Factor 2 and the total score. The criterion validity of the PCL total score varied considerably between outcomes, with moderate effect sizes for general and violent recidivism, institutional misconduct and violence, and small effect sizes for sexual and intimate partner violence recidivism. A moderator analysis indicated country and sex as the only significant predictors moderating the PCL scales' criterion validity. The total score and Factor 2 were less predictive in the United States than in Canada and Europe for institutional violence. Factor 1 was more predictive in females than males for general and violent recidivism. The present findings may support decision-makers in interpreting the prognostic value and limitations of the PCL scales in the criminal justice system. .
- 1 February 2024
- Published by American Psychological Association (APA) in Psychological Assessment
- Vol. 36 (2) , 134-146
Predictive and incremental validity of the Static-99, Static-99R, and STABLE-2007 for sexual recidivism: A diagnostic test accuracy network meta-analysis (DTA-NMA).
The Static-99, Static-99R, and STABLE-2007 are internationally well-established instruments for predicting static and dynamic risks of sexual recidivism in individuals convicted of sexual offenses. Previous meta-analyses assessed their predictive and incremental validity, but none has yet compared the two Static versions and the Static-STABLE combinations. Here, we implemented diagnostic test accuracy network meta-analysis (DTA-NMA) to compare all tests and identify optimal cutoffs in one comprehensive analysis. The DTA-NMA included 32 samples comprising 45,224 adult male individuals. More information was available on the Static-99 (22 samples; 34,316 individuals) and the Static-99R (13 samples; 27,243 individuals), compared to the Static-99/STABLE-2007 (three samples; 762 individuals), the Static-99R/STABLE-2007 (two samples; 2,972 individuals), and the STABLE-2007 (three samples; 816 individuals). The primary outcome was the area under the receiver operating characteristic curve (AUC). The secondary outcomes were sensitivity and specificity. Optimal cutoffs were determined using the Youden index. The AUC suggested moderate predictive validity for Static-99 and Static-99R, whereas STABLE-2007 had no predictive value. The optimal cutoff of Static-99R was suggested to have higher specificity than that of Static-99, whereas sensitivity was comparable between instruments. The notion of incremental validity for STABLE-2007 could not be confirmed. This work represents the first meta-analysis to compare Static-99, Static-99R, STABLE-2007, and their combinations in one analysis. Static-99R demonstrated the highest specificity in predicting the risk of sexual recidivism, indicating a potential advantage in detecting true nonrecidivists. The findings are discussed, considering the current recommendations for assessing the risk of sexual recidivism in the criminal justice system. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
- 1 February 2024
- Published by American Psychological Association (APA) in Psychological Assessment
- Vol. 36 (2) , 134-146
Predictive and incremental validity of the Static-99, Static-99R, and STABLE-2007 for sexual recidivism: A diagnostic test accuracy network meta-analysis (DTA-NMA).
The Static-99, Static-99R, and STABLE-2007 are internationally well-established instruments for predicting static and dynamic risks of sexual recidivism in individuals convicted of sexual offenses. Previous meta-analyses assessed their predictive and incremental validity, but none has yet compared the two Static versions and the Static-STABLE combinations. Here, we implemented diagnostic test accuracy network meta-analysis (DTA-NMA) to compare all tests and identify optimal cutoffs in one comprehensive analysis. The DTA-NMA included 32 samples comprising 45,224 adult male individuals. More information was available on the Static-99 (22 samples; 34,316 individuals) and the Static-99R (13 samples; 27,243 individuals), compared to the Static-99/STABLE-2007 (three samples; 762 individuals), the Static-99R/STABLE-2007 (two samples; 2,972 individuals), and the STABLE-2007 (three samples; 816 individuals). The primary outcome was the area under the receiver operating characteristic curve (AUC). The secondary outcomes were sensitivity and specificity. Optimal cutoffs were determined using the Youden index. The AUC suggested moderate predictive validity for Static-99 and Static-99R, whereas STABLE-2007 had no predictive value. The optimal cutoff of Static-99R was suggested to have higher specificity than that of Static-99, whereas sensitivity was comparable between instruments. The notion of incremental validity for STABLE-2007 could not be confirmed. This work represents the first meta-analysis to compare Static-99, Static-99R, STABLE-2007, and their combinations in one analysis. Static-99R demonstrated the highest specificity in predicting the risk of sexual recidivism, indicating a potential advantage in detecting true nonrecidivists. The findings are discussed, considering the current recommendations for assessing the risk of sexual recidivism in the criminal justice system. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
- Open Access
- 13 December 2023
- Published by Springer Nature in Journal of Experimental Criminology
- Vol. 21 (2) , 503-526
A multimodel meta-analysis assessing moderators of sexual recidivism as an indicator of treatment effectiveness in persons with sexual offense histories
Objectives: This meta-analysis tested whether multimodel inference provides more conclusive evidence than traditional single-hypothesis testing regarding predictors that moderate sexual recidivism as an indicator of treatment effectiveness in persons with sexual offense histories. Methods: A dataset including 35 studies equivalent to the meta-analysis by Holper et al. (Sex Abuse 2023; 0: 1–37) was used. Multimodel inference based on information theory tested 15 publication-, study-, treatment-, and individual-specific moderators. Results: Only risk level was related to sexual recidivism. A greater posttreatment reduction in sexual recidivism was apparent in high- and medium- compared to low-risk individuals. This moderator explained 77% of the residual heterogeneity. Conclusions: Compared to previous reports, the multimodel approach provided clearer evidence on which factors moderate sexual recidivism. Results corroborated the relevance of risk level, which relates to the risk-need-responsivity model. The findings may support treatment recommendations in persons with sexual offense histories in the criminal justice system.
- 13 December 2023
- Published by Springer Nature in Journal of Experimental Criminology
- Vol. 21 (2) , 503-526
Open AccessA multimodel meta-analysis assessing moderators of sexual recidivism as an indicator of treatment effectiveness in persons with sexual offense histories
Objectives: This meta-analysis tested whether multimodel inference provides more conclusive evidence than traditional single-hypothesis testing regarding predictors that moderate sexual recidivism as an indicator of treatment effectiveness in persons with sexual offense histories. Methods: A dataset including 35 studies equivalent to the meta-analysis by Holper et al. (Sex Abuse 2023; 0: 1–37) was used. Multimodel inference based on information theory tested 15 publication-, study-, treatment-, and individual-specific moderators. Results: Only risk level was related to sexual recidivism. A greater posttreatment reduction in sexual recidivism was apparent in high- and medium- compared to low-risk individuals. This moderator explained 77% of the residual heterogeneity. Conclusions: Compared to previous reports, the multimodel approach provided clearer evidence on which factors moderate sexual recidivism. Results corroborated the relevance of risk level, which relates to the risk-need-responsivity model. The findings may support treatment recommendations in persons with sexual offense histories in the criminal justice system.
- Open Access
- 16 March 2023
- Published by SAGE Publications in Sexual Abuse
- Vol. 36 (3) , 255-291
Moderators of Sexual Recidivism as Indicator of Treatment Effectiveness in Persons With Sexual Offense Histories: An Updated Meta-analysis
The present meta-analysis is an update of the meta-analysis by Schmucker and Lösel [Campbell Syst. Rev. 2017; 13: 1–75], which synthesized evidence on sexual recidivism as an indicator of treatment effectiveness in persons with sexual offense histories. The updated meta-analysis includes 37 samples comprising a total of 30,394 individuals with sexual offense histories, which is nearly three times the sample size reported by Schmucker and Lösel (2017: 28 samples, N = 9781). In line with Schmucker and Lösel (2017), the mean treatment effect was small with an odds ratio of 1.54 [95% CI 1.22, 1.95] ( p < .001). A moderator analysis suggested three predictors of importance, i.e., risk level, treatment specialization, and author confounding. Greater treatment effectiveness was suggested in high- and medium-compared to low-risk individuals and in specialized compared to non-specialized treatments. Authors affiliated with treatment programs reported larger effectiveness than independent authors. These findings were overall in line with Schmucker and Lösel (2017), though the effects of risk level and treatment specialization were stronger in the current meta-analysis. The findings of the updated meta-analysis reinforce the evidence for the first and second principle of the Risk-Need-Responsivity model. The results may support researchers and decision-makers in interpreting the current evidence on sexual recidivism as an indicator of treatment effectiveness, and, based on that, implement and carry out informative, methodologically sound evaluations of ongoing treatment programs in persons with sexual offense histories.
- 16 March 2023
- Published by SAGE Publications in Sexual Abuse
- Vol. 36 (3) , 255-291
Open AccessModerators of Sexual Recidivism as Indicator of Treatment Effectiveness in Persons With Sexual Offense Histories: An Updated Meta-analysis
The present meta-analysis is an update of the meta-analysis by Schmucker and Lösel [Campbell Syst. Rev. 2017; 13: 1–75], which synthesized evidence on sexual recidivism as an indicator of treatment effectiveness in persons with sexual offense histories. The updated meta-analysis includes 37 samples comprising a total of 30,394 individuals with sexual offense histories, which is nearly three times the sample size reported by Schmucker and Lösel (2017: 28 samples, N = 9781). In line with Schmucker and Lösel (2017), the mean treatment effect was small with an odds ratio of 1.54 [95% CI 1.22, 1.95] ( p < .001). A moderator analysis suggested three predictors of importance, i.e., risk level, treatment specialization, and author confounding. Greater treatment effectiveness was suggested in high- and medium-compared to low-risk individuals and in specialized compared to non-specialized treatments. Authors affiliated with treatment programs reported larger effectiveness than independent authors. These findings were overall in line with Schmucker and Lösel (2017), though the effects of risk level and treatment specialization were stronger in the current meta-analysis. The findings of the updated meta-analysis reinforce the evidence for the first and second principle of the Risk-Need-Responsivity model. The results may support researchers and decision-makers in interpreting the current evidence on sexual recidivism as an indicator of treatment effectiveness, and, based on that, implement and carry out informative, methodologically sound evaluations of ongoing treatment programs in persons with sexual offense histories.
- Open Access
- 5 March 2021
- Published by Springer Nature in BMC Psychiatry
- Vol. 21 (1) , 1-12
Conditional power of antidepressant network meta-analysis
Background Conditional power of network meta-analysis (NMA) can support the planning of randomized controlled trials (RCTs) assessing medical interventions. Conditional power is the probability that updating existing inconclusive evidence in NMA with additional trial(s) will result in conclusive evidence, given assumptions regarding trial design, anticipated effect sizes, or event probabilities. Methods The present work aimed to estimate conditional power for potential future trials on antidepressant treatments. Existing evidence was based on a published network of 502 RCTs conducted between 1979-2018 assessing acute antidepressant treatment in major depressive disorder (MDD). Primary outcomes were efficacy in terms of the symptom change on the Hamilton Depression Scale (HAMD) and tolerability in terms of the dropout rate due to adverse events. The network compares 21 antidepressants consisting of 231 relative treatment comparisons, 164 (efficacy) and 127 (tolerability) of which are currently assumed to have inconclusive evidence. Results Required sample sizes to achieve new conclusive evidence with at least 80% conditional power were estimated to range between N = 894 - 4190 (efficacy) and N = 521 - 1246 (tolerability). Otherwise, sample sizes ranging between N = 49 - 485 (efficacy) and N = 40 - 320 (tolerability) may require stopping for futility based on a boundary at 20% conditional power. Optimizing trial designs by considering multiple trials that contribute both direct and indirect evidence, anticipating alternative effect sizes or alternative event probabilities, may increase conditional power but required sample sizes remain high. Antidepressants having the greatest conditional power associated with smallest required sample sizes were identified as those on which current evidence is low, i.e., clomipramine, levomilnacipran, milnacipran, nefazodone, and vilazodone, with respect to both outcomes. Conclusions The present results suggest that conditional power to achieve new conclusive evidence in ongoing or future trials on antidepressant treatments is low. Limiting the use of the presented conditional power analysis are primarily due to the estimated large sample sizes which would be required in future trials as well as due to the well-known small effect sizes in antidepressant treatments. These findings may inform researchers and decision-makers regarding the clinical relevance and justification of research in ongoing or future antidepressant RCTs in MDD.
- 5 March 2021
- Published by Springer Nature in BMC Psychiatry
- Vol. 21 (1) , 1-12
Open AccessConditional power of antidepressant network meta-analysis
Background Conditional power of network meta-analysis (NMA) can support the planning of randomized controlled trials (RCTs) assessing medical interventions. Conditional power is the probability that updating existing inconclusive evidence in NMA with additional trial(s) will result in conclusive evidence, given assumptions regarding trial design, anticipated effect sizes, or event probabilities. Methods The present work aimed to estimate conditional power for potential future trials on antidepressant treatments. Existing evidence was based on a published network of 502 RCTs conducted between 1979-2018 assessing acute antidepressant treatment in major depressive disorder (MDD). Primary outcomes were efficacy in terms of the symptom change on the Hamilton Depression Scale (HAMD) and tolerability in terms of the dropout rate due to adverse events. The network compares 21 antidepressants consisting of 231 relative treatment comparisons, 164 (efficacy) and 127 (tolerability) of which are currently assumed to have inconclusive evidence. Results Required sample sizes to achieve new conclusive evidence with at least 80% conditional power were estimated to range between N = 894 - 4190 (efficacy) and N = 521 - 1246 (tolerability). Otherwise, sample sizes ranging between N = 49 - 485 (efficacy) and N = 40 - 320 (tolerability) may require stopping for futility based on a boundary at 20% conditional power. Optimizing trial designs by considering multiple trials that contribute both direct and indirect evidence, anticipating alternative effect sizes or alternative event probabilities, may increase conditional power but required sample sizes remain high. Antidepressants having the greatest conditional power associated with smallest required sample sizes were identified as those on which current evidence is low, i.e., clomipramine, levomilnacipran, milnacipran, nefazodone, and vilazodone, with respect to both outcomes. Conclusions The present results suggest that conditional power to achieve new conclusive evidence in ongoing or future trials on antidepressant treatments is low. Limiting the use of the presented conditional power analysis are primarily due to the estimated large sample sizes which would be required in future trials as well as due to the well-known small effect sizes in antidepressant treatments. These findings may inform researchers and decision-makers regarding the clinical relevance and justification of research in ongoing or future antidepressant RCTs in MDD.
- Open Access
- 7 September 2020
- Published by Springer Nature in BMC Psychiatry
- Vol. 20 (1) , 1-10
Comparative efficacy of placebos in short-term antidepressant trials for major depression: a secondary meta-analysis of placebo-controlled trials
Background: The issue of unblinded outcome-assessors and patients has repeatedly been stressed as a flaw in allegedly double-blind antidepressant trials. Unblinding bias can for example result from a drug‘s marked side effects. If such unblinding bias is present for a given drug, then it might be expected that the placebos of that drug are rated significantly less effective than that of other antidepressants. Methods: To test this hypothesis, the present exploratory analysis conducted a Bayesian network meta-analysis (NMA) comparing the efficacy of 19 different placebos in placebo-controlled trials provided in the dataset by Cipriani et al. (Lancet 2018; 391: 1357–66). Primary outcome was efficacy (continuous) estimated on the standardized mean difference (SMD) scale and defined as the pre-post change on the Hamilton Depression scale (HAMD-17), on which information was available in N = 258 trials. Results: Comparative placebo ranking suggested mirtazapine-placebo (SMD -2.0 [− 5.0–1.0 95% CrI]) to be the most, and amitriptyline- (SMD 1.2 [− 1.6–3.9 95% CrI]) and trazodone- (SMD 2.1 [− 0.9–5.2 95% CrI]) placebos to be the least effective placebos. Other placebos suggested to be more effective than amitriptyline- and trazodone-placebos (based on 95% CrIs excluding zero) were citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, and venlafaxine placebos. These NMA results were corroborated by the observation that the relative efficacy between drug and placebo was considerably larger for amitriptyline and trazodone than for instance mirtazapine, duloxetine, and venlafaxine, supported by a small and insignificant correlation between drug-efficacy and placebo-efficacy (r = − 0.202, p = 0.408). Discussion: The present exploratory NMA indicates that distinguishable side effects of older drugs may unblind outcome-assessors thus resulting in overestimation of the average drug-placebo difference and underrating bias in placebo-arms, particularly for the older antidepressant drugs amitriptyline and trazodone. If confirmed in prospective studies, these findings suggest that efficacy rankings for antidepressants are susceptible to bias and should be considered unreliable or misleading. The analysis is limited by the focus on the single-comparison placebos (76%, i.e., placebos assessed in two-arm trials), since double-comparison placebos (25%, i.e., placebos assessed in three-arm trials) are hard to interpret and therefore not included in the present interpretation. Another limitation is the problem of multiplicity, which was only approximately accounted for in the Bayesian NMA by modelling treatment effects as exchangeable.
- 7 September 2020
- Published by Springer Nature in BMC Psychiatry
- Vol. 20 (1) , 1-10
Open AccessComparative efficacy of placebos in short-term antidepressant trials for major depression: a secondary meta-analysis of placebo-controlled trials
Background: The issue of unblinded outcome-assessors and patients has repeatedly been stressed as a flaw in allegedly double-blind antidepressant trials. Unblinding bias can for example result from a drug‘s marked side effects. If such unblinding bias is present for a given drug, then it might be expected that the placebos of that drug are rated significantly less effective than that of other antidepressants. Methods: To test this hypothesis, the present exploratory analysis conducted a Bayesian network meta-analysis (NMA) comparing the efficacy of 19 different placebos in placebo-controlled trials provided in the dataset by Cipriani et al. (Lancet 2018; 391: 1357–66). Primary outcome was efficacy (continuous) estimated on the standardized mean difference (SMD) scale and defined as the pre-post change on the Hamilton Depression scale (HAMD-17), on which information was available in N = 258 trials. Results: Comparative placebo ranking suggested mirtazapine-placebo (SMD -2.0 [− 5.0–1.0 95% CrI]) to be the most, and amitriptyline- (SMD 1.2 [− 1.6–3.9 95% CrI]) and trazodone- (SMD 2.1 [− 0.9–5.2 95% CrI]) placebos to be the least effective placebos. Other placebos suggested to be more effective than amitriptyline- and trazodone-placebos (based on 95% CrIs excluding zero) were citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, and venlafaxine placebos. These NMA results were corroborated by the observation that the relative efficacy between drug and placebo was considerably larger for amitriptyline and trazodone than for instance mirtazapine, duloxetine, and venlafaxine, supported by a small and insignificant correlation between drug-efficacy and placebo-efficacy (r = − 0.202, p = 0.408). Discussion: The present exploratory NMA indicates that distinguishable side effects of older drugs may unblind outcome-assessors thus resulting in overestimation of the average drug-placebo difference and underrating bias in placebo-arms, particularly for the older antidepressant drugs amitriptyline and trazodone. If confirmed in prospective studies, these findings suggest that efficacy rankings for antidepressants are susceptible to bias and should be considered unreliable or misleading. The analysis is limited by the focus on the single-comparison placebos (76%, i.e., placebos assessed in two-arm trials), since double-comparison placebos (25%, i.e., placebos assessed in three-arm trials) are hard to interpret and therefore not included in the present interpretation. Another limitation is the problem of multiplicity, which was only approximately accounted for in the Bayesian NMA by modelling treatment effects as exchangeable.
- Open Access
- 28 July 2020
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 11, 633
Raising Placebo Efficacy in Antidepressant Trials Across Decades Explained by Small-Study Effects: A Meta-Reanalysis
Background: Recent meta-analyses reported placebo response rate in antidepressant trials to be stable since the 1970s. These meta-analyses however were limited in considering only linear time trends, assessed trial-level covariates based on single-model hypothesis testing only, and did not adjust for small-study effects (SSE), a well-known but not yet formally assessed bias in antidepressant trials. Methods: This secondary meta-analysis extends previous work by modeling nonlinear time trends, assessing the relative importance of trial-level covariates using a multimodel approach, and rigorously adjusting for SSE. Outcomes were placebo efficacy (continuous), based on the Hamilton Depression Scale, and placebo response rate. Results: Results suggested that any nonlinear time trends in both placebo efficacy (continuous) and response rate were best explained by SSE. Adjusting for SSE revealed a significant gradual increase in placebo efficacy (continuous) from 1979 to 2014. A similar observation was made for placebo response rate, but did not reach significance due higher susceptibility to SSE. By contrast, trial-level covariates alone were found to be insufficient in explaining time trends. Conclusion: The present findings contribute to the ongoing debate on antidepressant placebo outcomes and highlight the need to adjust for bias introduced by SSE. The results are of clinical relevance because SSE may affect the evaluation of success or failure in antidepressant trials.
- 28 July 2020
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 11, 633
Open AccessRaising Placebo Efficacy in Antidepressant Trials Across Decades Explained by Small-Study Effects: A Meta-Reanalysis
Background: Recent meta-analyses reported placebo response rate in antidepressant trials to be stable since the 1970s. These meta-analyses however were limited in considering only linear time trends, assessed trial-level covariates based on single-model hypothesis testing only, and did not adjust for small-study effects (SSE), a well-known but not yet formally assessed bias in antidepressant trials. Methods: This secondary meta-analysis extends previous work by modeling nonlinear time trends, assessing the relative importance of trial-level covariates using a multimodel approach, and rigorously adjusting for SSE. Outcomes were placebo efficacy (continuous), based on the Hamilton Depression Scale, and placebo response rate. Results: Results suggested that any nonlinear time trends in both placebo efficacy (continuous) and response rate were best explained by SSE. Adjusting for SSE revealed a significant gradual increase in placebo efficacy (continuous) from 1979 to 2014. A similar observation was made for placebo response rate, but did not reach significance due higher susceptibility to SSE. By contrast, trial-level covariates alone were found to be insufficient in explaining time trends. Conclusion: The present findings contribute to the ongoing debate on antidepressant placebo outcomes and highlight the need to adjust for bias introduced by SSE. The results are of clinical relevance because SSE may affect the evaluation of success or failure in antidepressant trials.
- Open Access
- 1 January 2020
- Published by Elsevier in eClinicalMedicine
- Vol. 18, 100219
Optimal doses of antidepressants in dependence on age: Combined covariate actions in Bayesian network meta-analysis
- 1 January 2020
- Published by Elsevier in eClinicalMedicine
- Vol. 18, 100219
Open AccessOptimal doses of antidepressants in dependence on age: Combined covariate actions in Bayesian network meta-analysis